Add BrightSurf on Google Email

How gut bacteria evade the immune system

Researchers identified a new type of flagellin in the human gut that binds to Toll-like receptor 5 without inducing an inflammatory response. This discovery provides a mechanism for the immune system to tolerate beneficial microbes while remaining responsive to pathogens.

SourceMax-Planck-Gesellschaft·JournalScience Immunology·TypeMeta-analysis·DateJan 16, 2023

UCalgary study offers new insight into deadly fungal invasion of the lungs

Researchers discovered that viral infections like SARS-CoV-2 and influenza destroy a natural immunity needed to resist fungal infections. This leads to impaired cooperation between white blood cells, allowing fungi to take root. The study reveals potential repurposing of current therapies to replace damaged antibodies.

SourceUniversity of Calgary·JournalScience Translational Medicine·TypeExperimental study·DateJan 12, 2023

Enhanced cancer immunotherapies through cytokine-labeled T cells

A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJan 10, 2023

More than two billion are infected with this disease; Vitamin D can help

Researchers found that vitamin D strengthens immune cells' ability to fight tuberculosis by producing cathelicidin toxin. Vitamin D treatment can prevent and treat the disease, particularly in populations exposed to high risk of infection. However, supplements do not protect against infection with tuberculosis.

SourceUniversity of Copenhagen - The Faculty of Health and Medical Sciences·JournalFrontiers in Immunology·TypeCase study·DateJan 6, 2023

Cellular messengers improve cancer therapy

Extracellular vesicles from immune cells have been shown to activate the immune system in mice with skin cancer, rendering them sensitive to checkpoint inhibitor therapy. The treatment improved survival rates when used in combination with checkpoint inhibitors.

SourceKarolinska Institutet·JournalCancer Immunology Research·TypeExperimental study·DateDec 22, 2022

New biomarker strategy devised to screen for, diagnose deadly heart complication from cancer treatment

Researchers at Michigan Medicine have developed a new biomarker-based strategy to screen for immune checkpoint inhibitor-induced myocarditis, which can cause muscle damage and liver injury. Early detection of these biomarkers can lead to earlier treatment and improved survival rates.

SourceMichigan Medicine - University of Michigan·JournalJACC CardioOncology·TypeObservational study·DateDec 20, 2022

Tracking plasma cell survival

A study by Osaka University tracked the survival of antibody-producing plasma cells, finding that most die shortly after immune response, but a small population can survive for months or years. The researchers identified molecular markers distinguishing these long-lived plasma cells from short-lived ones.

SourceOsaka University·JournalJournal of Experimental Medicine·TypeExperimental study·DateDec 14, 2022

Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateDec 10, 2022

CU Anschutz researchers find less-invasive treatment for certain head and neck cancers

Researchers at CU Anschutz Medical Campus have identified a less invasive way to treat HPV-unrelated head and neck squamous cell carcinomas by combining radiation with immunotherapy. The approach resulted in remarkable success rates, including 75% of patients experiencing major pathological responses or complete responses.

Researchers identify how certain immune cells contribute to worse survival in patients with HER2-positive breast cancer

Researchers found that HER2-positive breast cancer patients with high levels of tumour infiltrating lymphocytes in residual disease have significantly shorter overall survival. High levels of TILs are associated with poorer outcomes, while lower levels are linked to improved survival rates.

COVID-19 reactivates several latent viruses – particularly in ME patients

A recent study from Linköping University found that COVID-19 reactivated several latent viruses, including the Epstein-Barr virus, in people with chronic fatigue syndrome (ME/CFS). The study suggests that these reactivated viruses may contribute to the disease's symptoms and could potentially be used as a diagnostic tool.

SourceLinköping University·JournalFrontiers in Immunology·TypeExperimental study·DateNov 16, 2022

Investigating COVID-19 deaths for children and young people

A new study confirms that COVID-19 deaths among children and young people are rare, with most fatalities occurring in those with severe neurodisability or compromised immune systems. The analysis of detailed data showed that half of COVID-19 deaths occurred within 30 days of infection.

SourcePLOS·JournalPLOS Medicine·TypeObservational study·DateNov 8, 2022

Portland State study finds diet high in saturated fat can reprogram immune cells in mice

Researchers discovered that a ketogenic diet high in saturated fats can reprogram the mouse immune system, making it better at fighting off infections but more susceptible to systemic inflammatory conditions. The study also found that another type of fat, oleic acid, may be able to counteract the harmful effects of palmitic acid.

SourcePortland State University·JournaleLife·TypeExperimental study·DateNov 7, 2022

Researchers find treatment options for patients whose blood cancer relapses after CAR-T

Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.

Study finds that patients with cancer and a suppressed immune system are at high risk for severe COVID if treated with systemic drug therapies

A new study by researchers at Dana-Farber Cancer Institute found that patients with cancer and a weakened immune system who receive immunotherapies are more likely to experience severe COVID-19. The study also found that patients treated with other systemic treatments have milder symptoms, but still face increased risk of complications.

SourceDana-Farber Cancer Institute·JournalJAMA Oncology·TypeData/statistical analysis·DateNov 3, 2022

Hemophilia: Training the immune system to be tolerant

A study by the University of Bonn elucidated an important immune mechanism crucial for making hemophilia treatment effective. The researchers found that regulatory T cells can activate a self-destruct button on B cells against factor VIII, leading to its tolerance.

SourceUniversity of Bonn·JournalJournal of Clinical Investigation·TypeExperimental study·DateOct 26, 2022

Common, usually harmless group of bacteria associated with higher death rates in kidney patients

Researchers found a significant association between NTM infection and increased mortality in patients with end-stage renal disease. Early diagnosis and treatment may improve survival. NTM can cause nonspecific symptoms like fever and weight loss, and patients with compromised immune systems are at higher risk.

SourceMedical College of Georgia at Augusta University·JournalJournal of Investigative Medicine·DateOct 25, 2022